Abstract
Fluorescence in situ hybridization (FISH) has become a powerful technique for prognostic assessment in multiple myeloma (MM). However, the existence of associations between cytogenetic abnormalities compels us to re-assess the value of each abnormality. A total of 260 patients with MM at the time of diagnosis, enrolled in the GEM-2000 Spanish transplant protocol, have been analyzed by FISH in order to ascertain the independent influence on myeloma prognosis of IGH translocations, as well as RB and P53 deletions. Survival analyses showed that patients with t(4;14), RB or P53 deletions had a significantly shorter survival than patients without these abnormalities. However, patients with RB deletions without other abnormalities in FISH analysis, displayed a similar outcome to those patients without genetic changes by FISH (46 vs 54 months, P=0.3). In the multivariate analysis the presence of t(4;14), RB deletion associated with other abnormalities, age >60 years, high proportion of S-phase cells and advanced stage of the disease according to the International Staging System retained their independent prognostic influence. In summary, RB deletion as a sole abnormality does not lead to a shortening in the survival of MM patients, whereas t(4;14) confers the worst prognosis in MM patients treated with high-dose chemotherapy.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
San Miguel JF, García-Sanz R . Prognostic features of multiple myeloma. Best Pract Res Clin Haematol 2005; 18: 569–583.
Tricot G, Barlogie B, Jagannath S, Bracy D, Mattox S, Vesole DH et al. Poor prognosis in multiple myeloma is associated only with partial or complete deletions of chromosome 13 or abnormalities involving 11q and not with other karyotype abnormalities. Blood 1995; 86: 4250–4256.
Moreau P, Facon T, Leleu X, Morineau N, Huyghe P, Harousseau JL et al. Recurrent 14q32 translocations determine the prognosis of multiple myeloma, especially in patients receiving intensive chemotherapy. Blood 2002; 100: 1579–1583.
Fonseca R, Blood E, Rue M, Harrington D, Oken MM, Kyle RA et al. Clinical and biologic implications of recurrent genomic aberrations in myeloma. Blood 2003; 101: 4569–4575.
Shaughnessy Jr J, Tian E, Sawyer J, McCoy J, Tricot G, Jacobson J et al. Prognostic impact of cytogenetic and interphase fluorescence in situ hybridization-defined chromosome 13 deletion in multiple myeloma: early results of total therapy II. Br J Haematol 2003; 120: 44–52.
Chesi M, Nardini E, Brents LA, Schrock E, Ried T, Kuehl WM et al. Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3. Nat Genet 1997; 16: 260–264.
Chesi M, Bergsagel PL, Shonukan OO, Martelli ML, Brents LA, Chen T et al. Frequent dysregulation of the c-maf proto-oncogene at 16q23 by translocation to an Ig locus in multiple myeloma. Blood 1998; 91: 4457–4463.
Sawyer JR, Lukacs JL, Munshi N, Desikan KR, Singhal S, Mehta J et al. Identification of new nonrandom translocations in multiple myeloma with multicolor spectral karyotyping. Blood 1998; 92: 4269–4278.
Gertz MA, Lacy MQ, Dispenzieri A, Greipp PR, Litzow MR, Henderson KJ et al. Clinical implications of t(11;14)(q13;q32), t(4;14)(p16.3;q32), and -17p13 in myeloma patients treated with high-dose therapy. Blood 2005; 106: 2837–2840.
Mateo G, Castellanos M, Rasillo A, Gutierrez NC, Montalban MA, Martin ML et al. Genetic abnormalities and patterns of antigenic expression in multiple myeloma. Clin Cancer Res 2005; 11: 3661–3667.
Fonseca R, Harrington D, Oken MM, Dewald GW, Bailey RJ, Van Wier SA et al. Biological and prognostic significance of interphase fluorescence in situ hybridization detection of chromosome 13 abnormalities (delta13) in multiple myeloma: an eastern cooperative oncology group study. Cancer Res 2002; 62: 715–720.
Smadja NV, Bastard C, Brigaudeau C, Leroux D, Fruchart C . Hypodiploidy is a major prognostic factor in multiple myeloma. Blood 2001; 98: 2229–2238.
Hernández JM, González MB, Granada I, Gutierrez N, Chillon C, Ramos F et al. Detection of inv(16) and t(16;16) by fluorescence in situ hybridization in acute myeloid leukemia M4Eo. Haematologica 2000; 85: 481–485.
Greipp PR, San Miguel J, Durie BG, Crowley JJ, Barlogie B, Blade J et al. International staging system for multiple myeloma. J Clin Oncol 2005; 23: 3412–3420.
Calasanz MJ, Cigudosa JC, Odero MD, Ferreira C, Ardanaz MT, Fraile A et al. Cytogenetic analysis of 280 patients with multiple myeloma and related disorders: primary breakpoints and clinical correlations. Genes Chromosomes Cancer 1997; 18: 84–93.
Sawyer JR, Waldron JA, Jagannath S, Barlogie B . Cytogenetic findings in 200 patients with multiple myeloma. Cancer Genet Cytogenet 1995; 82: 41–49.
Tricot G, Sawyer JR, Jagannath S, Desikan KR, Siegel D, Naucke S et al. Unique role of cytogenetics in the prognosis of patients with myeloma receiving high-dose therapy and autotransplants. J Clin Oncol 1997; 15: 2659–2666.
Fonseca R, Debes-Marun CS, Picken EB, Dewald GW, Bryant SC, Winkler JM et al. The recurrent IgH translocations are highly associated with nonhyperdiploid variant multiple myeloma. Blood 2003; 102: 2562–2567.
Avet-Loiseau H, Facon T, Grosbois B, Magrangeas F, Rapp MJ, Harousseau JL et al. Oncogenesis of multiple myeloma: 14q32 and 13q chromosomal abnormalities are not randomly distributed, but correlate with natural history, immunological features, and clinical presentation. Blood 2002; 99: 2185–2191.
Chang H, Qi C, Yi QL, Reece D, Stewart AK . p53 gene deletion detected by fluorescence in situ hybridization is an adverse prognostic factor for patients with multiple myeloma following autologous stem cell transplantation. Blood 2005; 105: 358–360.
Kroger N, Schilling G, Einsele H, Liebisch P, Shimoni A, Nagler A et al. Deletion of chromosome band 13q14 as detected by fluorescence in situ hybridization is a prognostic factor in patients with multiple myeloma who are receiving allogeneic dose-reduced stem cell transplantation. Blood 2004; 103: 4056–4061.
Zojer N, Konigsberg R, Ackermann J, Fritz E, Dallinger S, Kromer E et al. Deletion of 13q14 remains an independent adverse prognostic variable in multiple myeloma despite its frequent detection by interphase fluorescence in situ hybridization. Blood 2000; 95: 1925–1930.
Mateos MV, Hernández JM, Hernández MT, Gutiérrez NC, Palomera L, Fuertes M et al. Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase I/II study. Blood 2006, E-pub ahead of print.
Fonseca R, Hoyer JD, Aguayo P, Jalal SM, Ahmann GJ, Rajkumar SV et al. Clinical significance of the translocation (11;14)(q13;q32) in multiple myeloma. Leukemia Lymphoma 1999; 35: 599–605.
Dewald GW, Therneau T, Larson D, Lee YK, Fink S, Smoley S et al. Relationship of patient survival and chromosome anomalies detected in metaphase and/or interphase cells at diagnosis of myeloma. Blood 2005; 106: 3553–3558.
Desikan R, Barlogie B, Sawyer J, Ayers D, Tricot G, Badros A et al. Results of high-dose therapy for 1000 patients with multiple myeloma: durable complete remissions and superior survival in the absence of chromosome 13 abnormalities. Blood 2000; 95: 4008–4010.
Facon T, Avet-Loiseau H, Guillerm G, Moreau P, Genevieve F, Zandecki M et al. Chromosome 13 abnormalities identified by FISH analysis and serum beta2-microglobulin produce a powerful myeloma staging system for patients receiving high-dose therapy. Blood 2001; 97: 1566–1571.
Pérez-Simón JA, García-Sanz R, Tabernero MD, Almeida J, Gonzalez M, Fernandez-Calvo J et al. Prognostic value of numerical chromosome aberrations in multiple myeloma: a FISH analysis of 15 different chromosomes. Blood 1998; 91: 3366–3371.
Drach J, Ackermann J, Fritz E, Kromer E, Schuster R, Gisslinger H et al. Presence of a p53 gene deletion in patients with multiple myeloma predicts for short survival after conventional-dose chemotherapy. Blood 1998; 92: 802–809.
Acknowledgements
We thank Arturo Touchard and Manuel Delgado for data managing; Belén González, M Ángeles Hernández and Isabel Isidro for technical assistance; and Mark Anderson from the University Technology Transfer Office. This study was partially supported by Spanish Myeloma Network Program (G03/136) and ‘Ministerio de Ciencia y Tecnologia’ grant (SAF 04/06587).
Author information
Authors and Affiliations
Consortia
Corresponding author
Appendix
Appendix
List of the members of GEM 2000 group: Hospital General de Albacete (Ángela Ibáñez, Félix Manso, Juan Carlos Gómez García); Hospital General Universitario de Alicante (Concepción Rivas González, Pascual Fernández Abellán); Hospital General Universitario Marina Alta Alicante (Rosa Ferrer Marco); Hospital Nuestra Señora de Sonsoles Ávila (Abelardo Bárez García); Complejo Asistencial Son Dureta Palma de Mallorca (Joan Besalduch Vidal, Mariana Canaro); Hospital Verge del Toro Mahon (Pilar Galán Alvarez); Hospital Son Llatzer Palma de Mallorca (Joan Bargay LLeonart); Hospital del Mar Barcelona (Eugenia Abella Monreal); Hospital Clínic Universitari Barcelona (Joan Bladé Creixenti, Laura Rosiñol Dach); Hospital Sant Pau Barcelona (Anna Sureda Balari); Clínica Corachan Barcelona (Alfons Modolell Roig); Hospital de Badalona Germans Trias i Pujol Barcelona (Josep María Ribera Santasusana); Hospital General de Manresa (Maricel Subirá); Complejo Hospitalario del Parc Tauli Barcelona (Juan Alfonso Soler Campos); Hospital del Espíritu Santo (Albert Altes); Hospital General de Mataró (Luis Rodríguez Fernández); Hospital Val D’Hebron Barcelona (Manuel Callis de Nadal); Hospital San Pedro de Alcántara Cáceres (Juan Miguel Bergua Burgués, Maria Luz Amigo Lozano); Hospital Punta de Europa Algeciras (Rosario Butrón Vila); Hospital General de Jerez de la Frontera (Ángel León Lara, José Luís Guzmán Zamudio, Patricio Leiva); Hospital General de Castellón (Maria Guinot Martinez, Raimundo García Boyero); Hospital Nuestra Señora de Alarcos Ciudad Real(Belén Hernández Ruiz); Hospital Clínico Universitario de Santiago de Compostela (José Luís Bello López, Natalia Alonso Vicente); Hospital Virgen de la Luz Cuenca (José Luís Guerra Moyano, María José Busto Medina); Hospital de Girona Josep Trueta (Santiago Gardella Company, Yolanda González Montes); Hospital General de Guadalajara (Félix Fuentes Galván, Miguel Díaz Morfa); Hospital de San Jorge Huesca (Fernando Puente Mangirón); Complejo Hospitalario de Jaén (Antonio Alcalá Muñoz); Hospital de Jaén (Pilar Mesa Valle); Hospital del Bierzo Ponferrada (Josefina Galende del Canto); Hospital Ramón y Cajal Madrid (José García Laraña); Hospital 12 de Octubre Madrid (Carlos Grande García, Juan José Lahuerta); Complejo Universitario San Carlos Madrid (Rafael Martínez Martínez); Hospital Universitario La Princesa Madrid (Adrián Alegre Amor, Beatriz Aguado Bueno, Flor Lara García-Escribano); Fundación Jiménez Díaz Madrid (Elena Prieto Pareja); Hospital Príncipe de Asturias Madrid (Carmen Burgaleta, Gemma Moreno Jiménez); Hospital Severo Ochoa Madrid (Pedro Sánchez Godoy); Hospital de Fuenlabrada Madrid (José Ángel Hernández Rivas); Hospital Universitario de Getafe (María del Carmen Monteserín); Hospital Universitario Virgen de la Victoria Málaga (Inmaculada Pérez Fernández, María José Moreno); Hospital General Morales Messeguer Murcia (Felipe de Arriba de la Fuente, José María Moraleda Jiménez); Hospital Nuestra señora del Rosell Cartagena (Jerónima Ibáñez García); Clínica Universitaria de Navarra Pamplona (Elena Carrascal, Felipe Prosper Cardoso, José Rifon); Hospital de Jarrio Oviedo (Ana Díaz Trapiella, Manuel Vargas Pabón); Hospital Central de Asturias Gijón (Consuelo Rayón Suárez, Dolores Carrera); Hospital Río Carrión Palencia (Fernando Ortega Rivas, José María Alonso Alonso); Complejo Hospitalario Materno-insular Las Palmas (José David González San Miguel ); Complejo Hospitalario Xeral-Cies Vigo (Carmen Albo López, Concha Poderos Baeta); Hospital Clínico de Salamanca (Jesús San Miguel Izquierdo); Hospital Universitario de Canarias Santa Cruz de Tenerife (Miguel Hernández García); Hospital Universitario Marques de Valdecilla Santander (Eulogio Conde García); Hospital General de Segovia (José Mariano Hernández Martín); Hospital Joan XXIII Tarragona (Andrés Llorente, Lourdes Escoda Teigell); Hospital Virgen de la Cinta Tortosa (Llorenç Font Ferré ); Hospital Nuestra Señora del Prado Talavera de la Reina (Fernando Solano Ramos); Hospital Virgen de la Salud Toledo (Felipe Casado Montero); Hospital Universitario La Fe Valencia (Isidro Jarque, Javier de la Rubia Comos); Hospital Doctor Peset Valencia (María José Sayas LLoris, Paz Ribas García); Hospital Arnau de Vilanova Valencia (Aurelio López Martínez, Encarna Monzó Castellano, José Mayans Ferrer); Hospital Clínico Universitario de Valencia (Inmaculada Blasco Blasco, Juan Carlos Hernández Boluda, Mará José Terol Casterá); Hospital General Universitario de Valencia (Félix Carbonell Ramón, Maite Otero Castelló); Fundación Instituto Valenciano de Oncología Valencia (Pablo Llorente Alegre); Hospital Francesc de Borja Gandia (María José Fernández, María Ángeles Ruiz Guinaldo); Hospital de Sagunto (Ana Carral Tatay, Isabel Navarro Gonzalo); Hospital Río Hortera Valladolid (Javier García Frade, María Jesús Peñarrubia); Hospital Clínico Universitario de Valladolid (Francisco Javier Fernández Calvo, Rebeca Cuello García); Hospital de Cruces Barakaldo (Elena Amutio Díez, Juan Carlos García Ruiz); Hospital de Galdakao (Jesús María Ojanguren Bergaz., Koldo Atutxa Aresti); Hospital Virgen de la Concha Zamora (Alejandro Martín García); Hospital Clínico Universitario Lozano Blesa Zaragoza (Luís Palomera Bernal); Hospital Miguel Server Zaragoza (Pilar Giraldo).
Rights and permissions
About this article
Cite this article
Gutiérrez, N., Castellanos, M., Martín, M. et al. Prognostic and biological implications of genetic abnormalities in multiple myeloma undergoing autologous stem cell transplantation: t(4;14) is the most relevant adverse prognostic factor, whereas RB deletion as a unique abnormality is not associated with adverse prognosis. Leukemia 21, 143–150 (2007). https://doi.org/10.1038/sj.leu.2404413
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.leu.2404413
Keywords
This article is cited by
-
Multiple myeloma with t(11;14): impact of novel agents on outcome
Blood Cancer Journal (2023)
-
Early monoclonal protein decline pattern is an independent prognostic factor in patients with multiple myeloma
Annals of Hematology (2020)
-
Distinct Clinical Features of Plasma Cell Myeloma Patients Exhibiting Dysmorphic Plasma Cells: Association with More Plasma Cells at Diagnosis
Indian Journal of Hematology and Blood Transfusion (2019)
-
Predicting long-term disease control in transplant-ineligible patients with multiple myeloma: impact of an MGUS-like signature
Blood Cancer Journal (2019)
-
Evaluation of Revised International Staging System (R-ISS) for transplant-eligible multiple myeloma patients
Annals of Hematology (2018)